We found that in the majority of SCLC cell lines, ATR and lurbinectedin were synergistic in the absence of ATM inhibitors, potentially due to the high frequency of loss‐of‐function TP53 mutations. This evidence concerns the gene ATR and small cell lung carcinoma.